TITLE

Characteristics of HIV-1 Serodiscordant Couples Enrolled in a Clinical Trial of Antiretroviral Pre-Exposure Prophylaxis for HIV-1 Prevention

AUTHOR(S)
Mujugira, Andrew; Baeten, Jared M.; Donnell, Deborah; Ndase, Patrick; Mugo, Nelly R.; Barnes, Linda; Campbell, James D.; Wangisi, Jonathan; Tappero, Jordan W.; Bukusi, Elizabeth; Cohen, Craig R.; Katabira, Elly; Ronald, Allan; Tumwesigye, Elioda; Were, Edwin; Fife, Kenneth H.; Kiarie, James; Farquhar, Carey; John-Stewart, Grace; Kidoguchi, Lara
PUB. DATE
October 2011
SOURCE
PLoS ONE;2011, Vol. 6 Issue 10, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: Stable heterosexual HIV-1 serodiscordant couples in Africa have high HIV-1 transmission rates and are a critical population for evaluation of new HIV-1 prevention strategies. The Partners PrEP Study is a randomized, double-blind, placebo-controlled trial of tenofovir and emtricitabine-tenofovir pre-exposure prophylaxis to decrease HIV-1 acquisition within heterosexual HIV-1 serodiscordant couples. We describe the trial design and characteristics of the study cohort. Methods: HIV-1 serodiscordant couples, in which the HIV-1 infected partner did not meet national guidelines for initiation of antiretroviral therapy, were enrolled at 9 research sites in Kenya and Uganda. The HIV-1 susceptible partner was randomized to daily oral tenofovir, emtricitabine-tenofovir, or matching placebo with monthly follow-up for 24-36 months. Results: From July 2008 to November 2010, 7920 HIV-1 serodiscordant couples were screened and 4758 enrolled. For 62% (2966/4758) of enrolled couples, the HIV-1 susceptible partner was male. Median age was 33 years for HIV-1 susceptible and HIV-1 infected partners [IQR (28-40) and (26-39) respectively]. Most couples (98%) were married, with a median duration of partnership of 7.0 years (IQR 3.0-14.0) and recent knowledge of their serodiscordant status [median 0.4 years (IQR 0.1-2.0)]. During the month prior to enrollment, couples reported a median of 4 sex acts (IQR 2-8); 27% reported unprotected sex and 14% of male and 1% of female HIV-1 susceptible partners reported sex with outside partners. Among HIV-1 infected partners, the median plasma HIV-1 level was 3.94 log10 copies/mL (IQR 3.31-4.53) and median CD4 count was 496 cells/mL (IQR 375-662); the majority (64%) had WHO stage 1 HIV-1 disease. Conclusions: Couples at high risk of HIV-1 transmission were rapidly recruited into the Partners PrEP Study, the largest efficacy trial of oral PrEP. (ClinicalTrials.gov NCT00557245)
ACCESSION #
73890176

 

Related Articles

  • HPTN 071 (PopART): A Cluster-Randomized Trial of the Population Impact of an HIV Combination Prevention Intervention Including Universal Testing and Treatment: Mathematical Model. Cori, Anne; Ayles, Helen; Beyers, Nulda; Schaap, Ab; Floyd, Sian; Sabapathy, Kalpana; Eaton, Jeffrey W.; Hauck, Katharina; Smith, Peter; Griffith, Sam; Moore, Ayana; Donnell, Deborah; Vermund, Sten H.; Fidler, Sarah; Hayes, Richard; Fraser, Christophe // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Background: The HPTN 052 trial confirmed that antiretroviral therapy (ART) can nearly eliminate HIV transmission from successfully treated HIV-infected individuals within couples. Here, we present the mathematical modeling used to inform the design and monitoring of a new trial aiming to test...

  • Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV. Sripan, Patumrat; Le Coeur, Sophie; Amzal, Billy; Ingsrisawang, Lily; Traisathit, Patrinee; Ngo-Giang-Huong, Nicole; McIntosh, Kenneth; Cressey, Tim R.; Sangsawang, Suraphan; Rawangban, Boonsong; Kanjanavikai, Prateep; Tréluyer, Jean-Marc; Jourdain, Gonzague; Lallemant, Marc; Urien, Saïk // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: Antiretroviral treatments decrease HIV mother-to-child transmission through pre/post exposure prophylaxis and reduction of maternal viral load. We modeled in-utero and intra-partum HIV transmissions to investigate the preventive role of various antiretroviral treatments...

  • Pre-Exposure Prophylaxis for HIV. Maynard, Tony // HIV Australia;Jul-Sep2005, Vol. 5 Issue 1, p23 

    Provides information on pre-exposure prophylaxis (PREP) for HIV which involves HIV negative people using antiretrovirals prior to engaging in activities that may lead to HIV transmission such as unprotected sex. Information on clinical trials to prove that using PREP could prevent infection;...

  • Treatment to Prevent Transmission of HIV-1. Cohen, Myron S.; Gay, Cynthia L. // Clinical Infectious Diseases;May2010 Supplement 3, Vol. 50, pS85 

    Antiretroviral therapy (ART) has the potential to prevent human immunodeficiency virus (HIV) transmission by reducing the concentration of HIV in blood and genital secretions. Indeed, mathematical models with favorable assumptions suggest the potential of ART to stop the spread of HIV infection....

  • Early Use of Antiretrovirals May Reduce HIV Transmission. Norman, Kayda // Applied Clinical Trials;Jun2011, Vol. 20 Issue 6, p17 

    The article discusses the findings of a study on a clinical trial known as the HPTN 052 in relation to the early use of oral antiretroviral therapy (ART). It states that the early use of ART may reduce the likelihood that a person with human immunodeficiency virus (HIV) will pass the virus to...

  • Ten Year Trends in Community HIV Viral Load in Barbados: Implications for Treatment as Prevention. Landis, R. Clive; Branch-Beckles, Songee Lynn; Crichlow, Shawna; Hambleton, Ian R.; Best, Anton // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Background: Treatment as prevention is a paradigm in HIV medicine which describes the public health benefit of antiretroviral therapy (ART). It is based on research showing substantial reductions in the risk of HIV transmission in persons with optimally suppressed HIV-1 Viral Loads (VL). The...

  • Antiretroviral Therapy and Reasons for Not Taking It among Men Having Sex with Men (MSM)—Results from the European MSM Internet Survey (EMIS). Marcus, Ulrich; Hickson, Ford; Weatherburn, Peter; Furegato, Martina; Breveglieri, Michele; Berg, Rigmor C.; Schmidt, Axel J.; null, null // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Background: The preventive effects of antiretroviral treatment (ART) on onward transmission of HIV are a major reason for broadening eligibility for ART. In the WHO European Region, surveillance reveals substantial differences in access to ART across regions and sub-populations. We analysed...

  • Prevalence of Transmitted HIV Drug Resistance in Iran between 2010 and 2011. Jahanbakhsh, Fatemeh; Hattori, Junko; Matsuda, Masakazu; Ibe, Shiro; Monavari, Seyed-Hamid R.; Memarnejadian, Arash; Aghasadeghi, Mohammad R.; Mostafavi, Ehsan; Mohraz, Minoo; Jabbari, Hossain; Kamali, Kianoush; Keyvani, Hossein; Azadmanesh, Kayhan; Sugiura, Wataru // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    Objective: Drug-resistant (DR) HIV emerges during combined antiretroviral treatment (cART), creating concern about widespread transmission of DR-HIV as cART is expanded in resource-limited countries. The aim of this study was to determine the predominant HIV-1 subtypes and prevalence of...

  • Attitudes of People in the UK with HIV Who Are Antiretroviral (ART) Naïve to Starting ART at High CD4 Counts for Potential Health Benefit or to Prevent HIV Transmission. Rodger, Alison J.; Phillips, Andrew; Speakman, Andrew; Gilson, Richard; Fisher, Martin; Wilkins, Ed; Anderson, Jane; Johnson, Margaret; O'Connell, Rebecca; Collins, Simon; Elford, Jonathan; Sherr, Lorraine; Lampe, Fiona C. // PLoS ONE;May2014, Vol. 9 Issue 5, p1 

    Objective: To assess if a strategy of early ART to prevent HIV transmission is acceptable to ART naïve people with HIV with high CD4 counts. Design: ASTRA is a UK multicentre, cross sectional study of 3258 HIV outpatients in 2011/12. A self-completed questionnaire collected sociodemographic,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics